AOD-9604 vs Retatrutide

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; a 2001 preclinical study in obese mice (PMID 11713213) demonstrated lipolytic effects and body weight reduction via this mechanism. Clinical trials were conducted in humans by Metabolic Pharmaceuticals, and Phase 2/3 data generated in Australia suggested modest weight loss effects; however, the primary trial results were never published in PubMed-indexed peer-reviewed journals, and the best indexed primary evidence for AOD-9604 remains that preclinical mouse study. AOD-9604 has no FDA approval and no approved indication in any jurisdiction; despite its human clinical program, the absence of published peer-reviewed primary trial data means clinical efficacy and safety cannot be independently evaluated, and no validated human dosing protocol has been established. The compound is currently available only as a research peptide. AOD-9604 is supplied as a lyophilized powder for research use; oral formulations were also evaluated in the clinical program as an alternative to subcutaneous delivery, though no commercial oral AOD-9604 product reached market. AOD-9604 evidence limitations The primary indexed evidence base for AOD-9604 consists of a 2001 preclinical study in obese mice (PMID 11713213) demonstrating beta-3 adrenergic receptor-mediated lipolysis and body weight reduction without IGF-1 elevation or blood glucose disruption. The Phase 2/3 human clinical program conducted by Metabolic Pharmaceuticals generated obesity trial data, but those primary results were never published in PubMed-indexed peer-reviewed journals, meaning the human efficacy and safety dataset cannot be independently evaluated. No validated human dosing protocol has been established for AOD-9604 in any jurisdiction, and no approved clinical indication exists. The absence of published human trial data represents a fundamental gap that precludes definitive statements about clinical efficacy, optimal administration, or long-term safety. AOD-9604 side effects and safety profile The safety data from AOD-9604's clinical program includes several notable findings: no elevation in IGF-1 levels was observed at studied doses — a key distinction from full-length growth hormone, where IGF-1 elevation drives concerns about cell proliferation and potential oncogenicity. No significant disruption of fasting glucose or insulin sensitivity was documented. No serious adverse events attributable to AOD-9604 were reported in published trial summaries. The absence of anabolic receptor activity (no binding to the GH receptor growth-promoting domain) is the proposed basis for this benign safety profile compared to GH itself. Long-term safety data does not exist due to the absence of Phase 3 completion and product approval. Research-grade AOD-9604 carries standard purity and contamination risks associated with unregulated compounding. Providers offering AOD-9604 through supervised clinical programs are searchable in the PeptideBase provider directory.

Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, combining the complementary metabolic actions of all three incretin and counterregulatory hormone pathways in a single weekly injection. The GLP-1 component drives satiety and insulin secretion, GIP enhances adipose lipid metabolism and further modulates appetite, and glucagon receptor activation increases energy expenditure — together producing greater weight loss than single or dual agonists in the same receptor class. A Phase 2 randomized controlled trial published in the New England Journal of Medicine demonstrated dose-dependent weight reductions of up to 24% of body weight at 48 weeks, among the largest reported for any pharmacological obesity treatment. Retatrutide has not received FDA approval; it is under Phase 3 registrational evaluation (TRIUMPH trials) as of 2025 for obesity, obstructive sleep apnea, and knee osteoarthritis. Retatrutide cost and access As of mid-2026, retatrutide has not received FDA approval and is not commercially available as a branded pharmaceutical. It is in late-stage (Phase 3) clinical development through Eli Lilly. Access pathways include: enrollment in active clinical trials (listed on ClinicalTrials.gov), research-use peptide vendors who supply retatrutide for laboratory/research contexts (not for human use), and a limited number of compounding pharmacies that compound investigational or pre-approval compounds under provider-supervised protocols. Cost per month of research-grade retatrutide from vendors varies considerably by quantity and formulation. Branded pharmaceutical pricing will be established at approval; given tirzepatide's pricing trajectory and the triple-agonist mechanism, analyst forecasts suggest a premium pricing position relative to existing GLP-1 agonists. Retatrutide vs survodutide: Survodutide (BI 456906, Boehringer Ingelheim + Zealand Pharma) is a dual GLP-1 and glucagon receptor agonist in Phase 3 development for MASH (metabolic dysfunction-associated steatohepatitis) and obesity. Compared to retatrutide, survodutide lacks the GIP receptor component; retatrutide's triple agonism adds GIP-mediated adipose lipid oxidation to the GLP-1 + glucagon combination. In trial comparisons, both compounds show substantial weight reductions (retatrutide 24.2% at 12mg/week in Phase 2; survodutide 18.7% at highest dose in Phase 2). Neither compound has a direct head-to-head trial yet. Both represent the next tier beyond tirzepatide in the GLP-1 + additional agonism category. Retatrutide's MASH indication (liver fat reduction) also overlaps with survodutide's primary development focus. The competitive landscape in this category is evolving rapidly as multiple Phase 3 readouts are expected through 2026–2027.